海洋中药治疗骨质疏松的用药规律及作用机制  

Medication pattern and mechanism of marine traditional Chinese medicine in the treatment of osteoporosis

作　　者：赖越 林轩 徐淼 刘欢 沈剑粦 黄文华 Lai Yue;Lin Xuan;Xu Miao;Liu Huan;Shen Jianlin;Huang Wenhua(The First Clinical Medical School,Guangdong Medical University,Zhanjiang 524023,Guangdong Province,China;Department of Environmental and Biological Engineering,Putian University,Putian 351100,Fujian Province,China;School of Basic Medicine,Fujian Medical University,Fuzhou 350100,Fujian Province,China;Department of Orthopaedics,The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University,Luzhou 646000,Sichuan Province,China;Central Laboratory,the Affiliated Hospital of Putian University,Putian 351100,Fujian Province,China;Guangdong Engineering Research Center for Translation of Medical 3D Printing Application,Guangdong Provincial Key Laboratory of Digital Medicine and Biomechanics,National Key Discipline of Human Anatomy,Southern Medical University,Guangzhou 510515,Guangdong Province,China)

机构地区：[1]广东医科大学第一临床医学院,广东省湛江市524023 [2]莆田学院环境与生物工程学院,福建省莆田市351100 [3]福建医科大学基础医学院,福建省福州市350100 [4]西南医科大学附属中医医院骨科,四川省泸州市646000 [5]莆田学院附属医院中心实验室,福建省莆田市351100 [6]南方医科大学基础医学院人体解剖学国家重点学科,广东省数字医学与生物力学重点实验室,广东省医学3D打印应用转化工程技术研究中心,广东省广州市510515

出　　处：《中国组织工程研究》2025年第17期3713-3723,共11页Chinese Journal of Tissue Engineering Research

基　　金：国家自然科学基金项目(82301785),项目负责人:沈剑粦。

摘　　要：背景:海洋中药为治疗骨质疏松提供了一种潜在有效且不易产生不良反应的方法。目的:应用数据挖掘和网络药理学方法分析并探讨中医临床治疗骨质疏松的用药规律及作用机制。方法:采用数据挖掘和网络药理学方法,对国家知识产权局批准的治疗骨质疏松的海洋中药专利处方进行用药模式和作用机制研究,并特别关注这些处方中的核心中药成分,利用超高效液相色谱串联质谱对牡蛎-续断-淫羊藿组成的复方药组核心成分进行全面的鉴定分析。结果与结论:①从国家知识产权局(SIPO)网站建立到2024-04-01,检索发现381项骨质疏松治疗的授权专利,共鉴定出48首含有海洋中药的中成药处方,这些处方包含183味中药,其中13种海洋中药用药频次共574次,单首专利组方中用药味数2-41种不等;②牡蛎是最常用的海洋中药,续断、淫羊藿、地黄、杜仲是最常用的非海洋中药;关联规则分析确定了牡蛎、续断和淫羊藿为核心药物群;网络药理学分析显示该核心药组治疗骨质疏松的核心靶点包括ALB、AKT1、TP53、PPARG和SRC;核心药组发挥疗效的核心成分为谷甾醇、甘草素、臭山羊碱、木犀草素、山奈酚;③GO与KEGG富集分析显示,Rap1/丝裂原活化蛋白激酶信号通路在核心药物组的骨质疏松作用机制中起着重要作用;④分子对接结果显示核心成分与核心靶点之间存在良好的相互作用;⑤超高效液相色谱串联质谱检测复方药组核心成分为木犀草素、谷甾醇、山奈酚等,与网络药理学鉴定的药物成分相符合;对复方药组成分进行定量分析得出,黄酮类化合物、萜类化合物以及生物碱这3类物质在药物成分占比中较大。BACKGROUND:Marine traditional Chinese medicine offers a potentially effective and less adverse treatment for osteoporosis.OBJECTIVE:To explore the pharmacological regulations and procedures of traditional Chinese medicine in treating osteoporosis through data mining and network pharmacology techniques.METHODS:Data mining and network pharmacology methods were used to study the medication pattern and mechanism of marine Chinese medicine patented prescriptions approved by China National Intellectual Property Administration for the treatment of osteoporosis,and special attention was paid to the core Chinese medicine constituents of these prescriptions.The core constituents of the compound drug group composed of oyster-Dipsacus asper-epimedium were comprehensively identified and analyzed by using ultra-high-performance liquid chromatography tandem mass spectrometry.RESULTS AND CONCLUSION:(1)We collected 381 authorized compound patents for the treatment of osteoporosis from the database inception to April 1,2024.Among these,48 patent groups utilized marine traditional Chinese medicine.These prescriptions contained 183 Chinese herbal medicines,of which 13 marine traditional Chinese medicines were used 574 times in total,and the number of flavors used in a single patented formula ranged from 2 to 41.(2)Oyster was the most frequently used marine ingredient,while Dipsacus asper,epimedium,Rehmannia glutinosa,Eucommia ulmoides Oliv.were the most frequent non-marine components.Association rule analysis identified oyster,Dipsacus asper,and epimedium as the core drug group.Network pharmacology analysis revealed that the core targets of this group for the treatment of osteoporosis included ALB,AKT1,TP53,PPARG,and SRC.Sitosterol,liquiritigenin,japonine,luteolin,and kaempferol were identified as the core components within the marine traditional Chinese medicine prescriptions.(3)The GO and KEGFG enrichment analyses suggested a potential association between the mechanism of the core drug group and the rap1/mapk signaling pathway in

关 键 词：骨质疏松 海洋中药 数据挖掘 网络药理学 分子对接 

分 类 号：R459.9[医药卫生—治疗学] R319[医药卫生—临床医学] R681